The GIGYF2 variants are not associated with Parkinson's disease in the mainland Chinese population

Cao, Li; Zhang, T.; Zheng, Liming; Wang, Ying; Wang, G.; Zhang, J.; Fei, Qiuping; Cui, Pei‐Jing; Wang, X.J.; Ma, Jianfang; Xiao, Qin; Chen, S.D.

doi:10.1016/j.parkreldis.2009.11.009

Cited by 8 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increased risk of PD by 37% was observed for C.3630A>G. GIGYF2 C.3630A>G is a key polymorphism in the previous PD studies (35,40,54). Since the power of C.3630A>G was moderate, further studies should be conducted to confirm this positive finding.…”

Section: Discussionmentioning

confidence: 80%

“…A previous study strongly supported that GIGYF2 was a causal factor of PD in the familial study (40). However, other studies showed a lack of association in sporadic PD studies (33,35,54). Subgroup analysis by the PD family history is required to establish the role of genetic factors in the pathogenesis of PD.…”

Section: Discussionmentioning

confidence: 95%

“…Previously, several studies have performed an association study between the GIGYF2 polymorphisms and PD (30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43). Among them, four studies showed a positive association of the GIGYF2 polymorphisms with PD (30-33), whereas the other 10 studies showed a negative association (34)(35)(36)(37)(38)(39)(40)(41)(42)(43).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Meta-analyses of seven GIGYF2 polymorphisms with Parkinson’s disease

Dai

Wang²,

Zhou

et al. 2014

Biomedical Reports

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects ~2% of the global population aged ≥65 years. Grb10-interacting GYF protein-2 (GIGYF2) can influence the development of PD through the regulation of insulin-like growth factor-1. The aim of the present meta-analysis study was to establish the contribution of polymorphisms to PD. The study was conducted based on nine eligible studies consisting of 7,246 PD patients and 7,544 healthy controls. The results indicated that the C.3630A>G polymorphism increased the risk of PD by 37% [P=0.008; odds ratio (OR), 1.37; 95% confidence interval (CI), 1.08-1.73] and that the C.167G>A polymorphism was significantly associated with PD (P=0.003; OR, 3.67; 95% CI, 1.56-8.68). The meta-analyses of the other five polymorphisms (C.1378C>A, C.1554G>A, C.2940A>G, C.1370C>A and C.3651G>A) did not reveal any significant associations. The present meta-analyses of the genetic polymorphisms may provide a comprehensive overview of this PD candidate gene for future studies.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analyses of seven GIGYF2 polymorphisms with Parkinson’s disease

Dai

Wang²,

Zhou

et al. 2014

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…12,13,18,19,26,27,29 There has been only one prior study of the effect of c.297T>C, which identified no significant difference among 52 patients with familial PD and 56 healthy controls from mainland China. 26 However, there remains much uncertainty as to the effects of these variants on the pathogenesis of PD, which only further study will elucidate.…”

Section: Discussionmentioning

confidence: 99%

“…12 Since the GIGYF2 gene was first identified, studies in Portuguese, US, Australian, Norwegian, Belgian, Spanish, French, Italian, Japanese, Singaporean and Chinese populations have provided conflicting data on the causal role of this gene. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] However, around half of these studies only analyzed some or all of the reported pathogenic mutations, rather than comprehensively sequencing the GIGYF2 gene. In our previous study, we directly sequenced the GIGYF2 gene and identified nine missense variants and 14 polymorphisms.…”

Section: Introductionmentioning

confidence: 99%

Follow-up study of variants of the GIGYF2 gene in Chinese patients with Parkinson’s disease

Wang

Guo

Zhang

et al. 2011

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Genetic Testing in Parkinson's Disease

et al. 2023

View full text Add to dashboard Cite

Genetic testing for persons with Parkinson's disease is becoming increasingly common. Significant gains have been made regarding genetic testing methods, and testing is becoming more readily available in clinical, research, and direct‐to‐consumer settings. Although the potential utility of clinical testing is expanding, there are currently no proven gene‐targeted therapies, but clinical trials are underway. Furthermore, genetic testing practices vary widely, as do knowledge and attitudes of relevant stakeholders. The specter of testing mandates financial, ethical, and physician engagement, and there is a need for guidelines to help navigate the myriad of challenges. However, to develop guidelines, gaps and controversies need to be clearly identified and analyzed. To this end, we first reviewed recent literature and subsequently identified gaps and controversies, some of which were partially addressed in the literature, but many of which are not well delineated or researched. Key gaps and controversies include: (1) Is genetic testing appropriate in symptomatic and asymptomatic individuals without medical actionability? (2) How, if at all, should testing vary based on ethnicity? (3) What are the long‐term outcomes of consumer‐ and research‐based genetic testing in presymptomatic PD? (4) What resources are needed for clinical genetic testing, and how is this impacted by models of care and cost‐benefit considerations? Addressing these issues will help facilitate the development of consensus and guidelines regarding the approach and access to genetic testing and counseling. This is also needed to guide a multidisciplinary approach that accounts for cultural, geographic, and socioeconomic factors in developing testing guidelines. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

show abstract

The GIGYF2 variants are not associated with Parkinson's disease in the mainland Chinese population

Cited by 8 publications

References 12 publications

Meta-analyses of seven GIGYF2 polymorphisms with Parkinson’s disease

Meta-analyses of seven GIGYF2 polymorphisms with Parkinson’s disease

Follow-up study of variants of the GIGYF2 gene in Chinese patients with Parkinson’s disease

Genetic Testing in Parkinson's Disease

Contact Info

Product

Resources

About